Individual and combination of mdvi-1 and nutlin-3 for topical or intravitreal ophthalmic use

Abstract

Disclosed are pharmaceutical compositions comprising mdivi-1 and nutlin-3, individually and in combination, for topical or intravitreal ophthalmic delivery and a method of treatment comprising administering said composition when indicated for glaucoma, optic neuropathies including Leber Hereditary Optic Neuropathy, arteritic or non-arteritic Ischemic Optic Neuropathy, and retinal artery and vein occlusions.

What is claimed is: 
     
         1 . A method of treating ischemic optic neuropathy in an eye of a person in need thereof, the method comprising administering, to the person, a composition comprising a therapeutically effective amount of mdivi-1. 
     
     
         2 . The method of  claim 1 , wherein the composition is administered to said person once to four times per day. 
     
     
         3 . The method of  claim 1 , wherein the composition is administered once per week. 
     
     
         4 . The method of  claim 1 , wherein the composition is administered once. 
     
     
         5 . The method of  claim 1 , wherein the composition is formulated for intravitreal injection or topical delivery. 
     
     
         6 . The method of  claim 5 , wherein the composition is formulated for intravitreal injection. 
     
     
         7 . The method of  claim 1 , wherein the composition further comprises a preservative. 
     
     
         8 . The method of  claim 7 , wherein the preservative is less than 0.005 wt. %. 
     
     
         9 . The method of  claim 7 , wherein the preservative is benzalkonium chloride.